The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Stock and Other Ownership Interests - Celgene
nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).
 
Margaret A. Tempero
Consulting or Advisory Role - AstraZeneca; Celgene; Champions Oncology; Myriad Genetics; Nucana; Proacta; Targovax
Research Funding - Celgene
 
Dana Backlund Cardin
Consulting or Advisory Role - Merrimack
Research Funding - Celgene; Genentech; Incyte; Synta
 
Andrew Biankin
Honoraria - AstraZeneca; Celgene; Clovis Oncology
Consulting or Advisory Role - Celgene; Clovis Oncology; Cure Forward
Speakers' Bureau - Celgene
Patents, Royalties, Other Intellectual Property - Cure Forward
Travel, Accommodations, Expenses - Celgene; Clovis Oncology
 
David Goldstein
Stock and Other Ownership Interests - Sirtex Medical
Research Funding - Amgen (Inst); Celgene (Inst); pfizer (Inst)
 
Malcolm Moore
Consulting or Advisory Role - Celgene
Research Funding - Celgene
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bayer; Celgene; epson; Lilly; novartis; Roche
Speakers' Bureau - Amgen; Bayer; Celgene; roche; sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Roche (Inst)
 
Hanno Riess
Consulting or Advisory Role - Bayer; Celgene; GlaxoSmithKline; Roche Pharma AG
Speakers' Bureau - Bayer; Celgene; GlaxoSmithKline; Roche Pharma AG
 
Teresa Macarulla
No Relationships to Disclose
 
Lotus Yung
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Mingyu Li
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Brian Lu
No Relationships to Disclose